Healthcare Industry News: radiosurgery
News Release - July 22, 2009
First CyberKnife System in Rhode Island InstalledInstallation at Rhode Island Hospital Brings CyberKnife radiosurgery to 40th State*
SUNNYVALE, Calif., July 22 (Healthcare Sales & Marketing Network) -- Accuray Incorporated (Nasdaq: ARAY ), a global leader in the field of radiosurgery, announced today that radiosurgery Center of Rhode Island, LLC, installed a CyberKnife(R) Robotic radiosurgery System within Rhode Island Hospital in Providence, marking the first CyberKnife System in Rhode Island.
"This new technology will allow us to provide the most targeted treatment for our cancer patients," said David Wazer, M.D., medical director of the radiosurgery Center of Rhode Island, LLC. "CyberKnife's non-invasive design provides maximum benefit for the patient through focused radiation while also providing a shorter radiation cycle and a more comfortable experience with fewer side effects that affect quality of life."
CyberKnife radiosurgery offers a non-invasive treatment for cancerous and non-cancerous tumors. By incorporating robotic mobility and the ability to image throughout the treatment, the CyberKnife System delivers high-doses of radiation to destroy tumors and minimize damage to surrounding healthy tissue. Treatments are completed on an outpatient basis in one to five sessions and patients can typically resume their normal activities immediately following treatment.
radiosurgery Center of Rhode Island, LLC, is a partnership of Rhode Island Hospital and 21st Century Oncology. For more information on this center, please visit www.cyberkniferi.com
* Figure includes the U.S. Territory of Puerto Rico.
About the CyberKnife(R) Robotic radiosurgery System
The CyberKnife Robotic radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
Accuray Incorporated (Nasdaq: ARAY ), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 60,000 patients worldwide and currently more than 164 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to commercialization of products, clinical studies, and regulatory review and approval are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2008 fiscal year, as updated in our Form 10-Q filed on May 6, 2009 and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsHong Kong Sanatorium & Hospital Transforms Cancer Care in Asia with Treatment of First Patient Using the Accuray Radixact(R) System and ClearRT(TM) Helical Fan-Beam kVCT Imaging
Accuray Expands CyberKnife(R) System Versatility with Integration of RaySearch's RayStation Treatment Planning System
RayStation Latest Release, Now with Support for Accuray's CyberKnife(R) System